Angiogenin, angiopoietin-1, angiopoietin-2, and endostatin serum levels in inflammatory bowel disease

2011 ◽  
Vol 17 (4) ◽  
pp. 963-970 ◽  
Author(s):  
Konstantinos A. Oikonomou ◽  
Andreas N. Kapsoritakis ◽  
Anastasia I. Kapsoritaki ◽  
Anastassios C. Manolakis ◽  
Elisavet K. Tiaka ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Serum Levels ◽  
Inflammatory Bowel ◽  
Angiopoietin 2 ◽  
Angiopoietin 1

Positive Association between Leptin Serum Levels and Endoscopic Activity in Inflammatory Bowel Disease

2017 ◽  
Vol 152 (5) ◽  
pp. S766
Author(s):  
Fabiola Trejo-Vazquez ◽  
Idalia Garza-Veloz ◽  
Alejandra Villela-Ramirez ◽  
panfilo Mauricio-Saucedo ◽  
Yolanda Ortiz Castro ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Positive Association ◽  
Serum Levels ◽  
Inflammatory Bowel

Tu1881 Immunohistochemical Expression of Angiopoietin 1 (Ang1) and Microvessels Density in Colon of Patients With Inflammatory Bowel Disease (IBD)

2012 ◽  
Vol 142 (5) ◽  
pp. S-868
Author(s):  
Pablo M. Linares ◽  
Maria Encarnacion Fernandez Contreras ◽  
Alicia Algaba ◽  
Mercedes Guijarro-Rojas ◽  
Fernando Bermejo ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Immunohistochemical Expression ◽  
Inflammatory Bowel ◽  
Microvessels Density ◽  
Angiopoietin 1

scholarly journals P186 Association between anti-TNF serum levels and mucosal healing in inflammatory bowel disease

2017 ◽  
Vol 11 (suppl_1) ◽  
pp. S171-S171
Author(s):  
M. Chaparro ◽  
M. Barreiro-de Acosta ◽  
A. Echarri ◽  
R. Almendros ◽  
J. Barrio ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Serum Levels ◽  
Mucosal Healing ◽  
Inflammatory Bowel

scholarly journals Relationship between Serum Adalimumab Levels and Clinical Outcome in the Treatment of Inflammatory Bowel Disease

2019 ◽  
Vol 37 (6) ◽  
pp. 444-450 ◽  
Author(s):  
Joaquín Hinojosa ◽  
Fernando Muñoz ◽  
Gregorio Juan Martínez-Romero
Keyword(s):  
Inflammatory Bowel Disease ◽  
Clinical Outcome ◽  
Maintenance Therapy ◽  
Bowel Disease ◽  
Clinical Remission ◽  
Meta Analysis ◽  
Serum Levels ◽  
Mucosal Healing ◽  
Endoscopic Remission ◽  
Inflammatory Bowel

Background: Adalimumab (ADA) is an anti-tumor necrosis factor agent that has been shown to be effective in inducing and maintaining remission in adult patients with inflammatory bowel disease. The relationship between the ADA trough levels and clinical efficacy has been demonstrated, but there is variability in the definition of the most suitable range for its clinical applicability. Summary: A review of published studies during the last 5 years on ADA serum levels and its relationship with the clinical outcome was performed. The studies selected included 7 observational studies, a systematic review, a meta-analysis and a post hoc analysis of a clinical trial. The reported ADA levels that discriminate patients in clinical remission from those with active disease range from 4.5 to 8 µg/mL. This therapeutic range varies when considering endoscopic remission (7.5 to >13.9 µg/mL). Although the sample of patients with ulcerative colitis is small, a tendency to reach higher levels of ADA is observed in both clinical and endoscopic remission. Key Messages: The optimal therapeutic cut-off point of serum ADA levels ranges from 4.5–5 to 12 µg/mL, where ADA levels are associated with an adequate clinical monitoring of the disease during maintenance therapy. These ranges vary according to the target, suggesting levels of 4.8 µg/mL as the cut-off for clinical remission and levels ≥7.5 µg/mL for mucosal healing/endoscopic response. Controlled prospective studies are required to determine the optimal therapeutic interval of ADA serum levels both as induction and as maintenance therapy.

741 Low Serum Levels of IgG4 Antibodies May Function as a Biomarker of Severity in Inflammatory Bowel Disease

2019 ◽  
Vol 114 (1) ◽  
pp. S435-S436
Author(s):  
Filippos Koutroumpakis ◽  
Anna E. Philipps ◽  
Dhiraj Yadav ◽  
Claudia Ramos Rivers ◽  
Marc Schwartz ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Serum Levels ◽  
Inflammatory Bowel ◽  
Low Serum

scholarly journals Imbalance of tissue inhibitors of metalloproteinases (TIMP) – 1 and – 4 serum levels, in patients with inflammatory bowel disease

2008 ◽  
Vol 8 (1) ◽  
Author(s):  
Andreas N Kapsoritakis ◽  
Anastasia I Kapsoritaki ◽  
Ioanna P Davidi ◽  
Vasilios D Lotis ◽  
Anastasios C Manolakis ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Serum Levels ◽  
Tissue Inhibitors Of Metalloproteinases ◽  
Tissue Inhibitors ◽  
Inflammatory Bowel
Sign in / Sign up

Export Citation Format

Share Document